Is Edap Tms S.a. (EDAP) a Buy, Sell, or Hold?
NASDAQ : EDAP
Edap Tms S.a.
$4.755 USD
-$0.03 (-0.52%)
- Volume
- 28.86K
- Average Volume
- 39.24K
- Market Capitalization
- $178.23M
- P/E Ratio
- -6.18
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $5.05
- Year Low
- $1.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.34
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ryan Rhodes |
| Industry | Medical - Specialties |
| Sector | Healthcare |
| Current Symbol | EDAP |
| CUSIP | 268311107 |
| CIK | 0001041934 |
| Web | https://focalone.com |
| Phone | 33 4 72 15 31 50 |
| Currency | USD |
| Employees | 289 |
| Country | FR |
Liquidity
| Debt-to-Equity Ratio | 0.23 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.34 |
| Quick Ratio | 0.99 |
| Cash Ratio | 0.40 |
Sales & Book Value
| Annual Sales | $70.75M |
| Price / Sales | 2.48 |
| Cash Flow | -0.51 |
| Price / Cash Flow | -9.25 |
| Price / Book | 17.64 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -52.45% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.78 |
| Trailing P/E Ratio | -6.18 |
| PEG Ratio | 0.17 |
| P/E Growth | 0.17 |
| Net Income | -$29.34M |
| Net Margin | -41.70% |
| Pretax Margin | -41.11% |
| Return on Equity | -148.90% |
| Return on Assets | -41.67% |
Financials Score
| AltmanZ Score | -1.10 |
| Piotroski Score | 3.00 |
| Working Capital | 12.86M |
| Total Assets | 72.06M |
| Ebit | -25.08M |
| Market Cap | 155.97M |
| Total Liabilities | 61.96M |
Poll Results
About Edap Tms S.a. (NASDAQ:EDAP) Stock
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the tre ... atment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.
Edap Tms Unveils FocalTherics Pivot, Targets 40% Growth on HIFU Expansion
2026-06-01 15:06:01
Edap Tms NASDAQ: EDAP used its 2026 FocalTherics Investor Day to outline its shift toward becoming a “high-growth, pure-play robotic focal therapy company,” with management emphasizing the company's Focal One robotic high-intensity focused ultrasound, or HIFU, platform for prostate cancer and future indications.
2026-05-29 07:30:00
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
2026-05-29 07:30:00
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
2026-05-21 07:30:00
, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
2026-05-14 07:30:00
, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of EDAP's Focal One Robotic HIFU and Telix's PSMA PET imaging products in the management of prostate cancer.
EDAP | Focal One to Host Investor Day on June 1, 2026
2026-05-13 16:30:00
, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026.
EDAP | Focal One to Host Investor Day on June 1, 2026
2026-05-13 16:30:00
, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026. The presentation will be led by members of the Company's Executive Leadership Team and will include remarks from a prominent urologic surgeon and expert in focal therapy and Focal One HIFU.
EDAP TMS S.A. (EDAP) Q1 2026 Earnings Call Transcript
2026-05-07 18:41:18
EDAP TMS S.A. (EDAP) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Edap Tms S.a. (EDAP) stock price?
-
Edap Tms S.a.(NASDAQ:EDAP) stock price is $4.755 in the last trading session. During the trading session, EDAP stock reached the peak price of $5.05 while $1.21 was the lowest point it dropped to. The percentage change in EDAP stock occurred in the recent session was --0.52% while the dollar amount for the price change in EDAP stock was -$0.03.
-
EDAP's industry and sector of operation?
-
The NASDAQ listed EDAP is part of Medical - Specialties industry that operates in the broader Healthcare sector.
-
Who are the executives of EDAP?
-
Kenneth Mobeck | Chief Financial Officer
Ryan Rhodes | Chief Executive Officer & Director
Steven Annen | Executive Vice President of Marketing & Product Management
Frederic Pech | President of EDAP TMS France
Jean-Francois Bachelard | President & Chief Executive Officer of Edaptechnomed Co. Ltd. -
How many employees does EDAP have?
-
Number of EDAP employees currently stands at 289. EDAP operates from Parc dActivites la Poudrette-Lamartine, Vaulx-en-Velin, None 69120, FR.
-
Link for EDAP official website?
-
Official Website of EDAP is: https://focalone.com
-
How do I contact EDAP?
-
EDAP could be contacted at phone #33 4 72 15 31 50 and can also be accessed through its website. EDAP operates from Parc dActivites la Poudrette-Lamartine, Vaulx-en-Velin, None 69120, FR.
-
How many shares of EDAP are traded daily?
-
The average number of EDAP shares traded daily for last 3 months was 39.24K.
-
What is the market cap of EDAP currently?
-
The market value of EDAP currently stands at $178.23M with its latest stock price at $4.755